Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)
China · Delayed Price · Currency is CNY 5.18
-0.04 (-0.77%)
Jul 31, 2026, 3:04 PM CST
SHE:002252 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 34,150 | 41,873 | 47,685 | 53,164 | 42,737 | 45,972 | |
Market Cap Growth | -26.03% | -12.19% | -10.30% | 24.40% | -7.04% | -7.84% |
Enterprise Value | 35,910 | 42,775 | 43,990 | 48,939 | 39,357 | 42,858 |
Last Close Price | 5.18 | 6.28 | 7.12 | 7.81 | 6.17 | 6.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.60 | 26.55 | 21.74 | 29.88 | 22.73 | 35.51 |
Forward PE | 18.50 | 17.14 | 18.28 | 22.86 | 96.49 | 96.49 |
PS Ratio | 4.98 | 5.70 | 5.83 | 6.68 | 6.51 | 10.72 |
PB Ratio | 1.05 | 1.29 | 1.49 | 1.79 | 1.48 | 1.78 |
P/TBV Ratio | 1.45 | 1.78 | 1.81 | 2.19 | 1.79 | 2.21 |
P/FCF Ratio | - | - | - | 29.10 | 28.49 | 42.20 |
P/OCF Ratio | - | - | - | 23.34 | 24.77 | 35.53 |
PEG Ratio | - | 3.43 | 1.66 | 2.29 | 2.29 | 2.29 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.24 | 5.82 | 5.38 | 6.15 | 5.99 | 10.00 |
EV/EBITDA Ratio | 22.96 | 23.53 | 19.14 | 19.76 | 18.14 | 26.52 |
EV/EBIT Ratio | 26.92 | 26.80 | 21.02 | 21.13 | 19.79 | 29.31 |
EV/FCF Ratio | - | - | - | 26.79 | 26.24 | 39.34 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.12 | 0.12 | 0.00 | 0 | 0 | 0 |
Debt / EBITDA Ratio | 2.49 | 2.14 | 0.01 | 0.00 | 0.00 | 0.01 |
Debt / FCF Ratio | - | - | - | 0.00 | 0.00 | 0.01 |
Net Debt / Equity Ratio | 0.05 | 0.06 | -0.09 | -0.14 | -0.15 | -0.11 |
Net Debt / EBITDA Ratio | 1.11 | 0.99 | -1.29 | -1.69 | -1.94 | -1.83 |
Net Debt / FCF Ratio | -1.25 | -2.52 | 3.34 | -2.30 | -2.81 | -2.71 |
Asset Turnover | 0.19 | 0.21 | 0.25 | 0.26 | 0.23 | 0.16 |
Inventory Turnover | 0.90 | 0.97 | 1.22 | 1.37 | 1.14 | 0.78 |
Quick Ratio | 1.67 | 1.62 | 2.90 | 2.22 | 3.16 | 2.77 |
Current Ratio | 3.73 | 3.64 | 5.61 | 3.87 | 5.22 | 5.26 |
Return on Equity (ROE) | 4.08% | 4.90% | 7.12% | 6.08% | 6.85% | 5.05% |
Return on Assets (ROA) | 2.34% | 2.79% | 3.99% | 4.64% | 4.31% | 3.47% |
Return on Invested Capital (ROIC) | 3.26% | 4.18% | 6.44% | 7.46% | 6.89% | 5.34% |
Return on Capital Employed (ROCE) | 3.90% | 4.60% | 6.50% | 7.80% | 6.90% | 5.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.89% | 3.77% | 4.60% | 3.35% | 4.40% | 2.82% |
FCF Yield | -4.11% | -1.70% | -1.86% | 3.44% | 3.51% | 2.37% |
Dividend Yield | 0.93% | 0.77% | 0.98% | 0.38% | 0.49% | 0.42% |
Payout Ratio | 28.12% | 16.40% | 20.05% | 11.36% | 10.04% | 13.02% |
Buyback Yield / Dilution | 0.89% | 0.51% | -0.39% | 2.23% | - | -5.28% |
Total Shareholder Return | 1.81% | 1.28% | 0.59% | 2.61% | 0.49% | -4.85% |